WhatsApp Skip to main content

Dr. Harsh J Shah

What Does Your GIST Gene Report Mean? KIT, PDGFRA, SDH

Last updated: 17-Nov-2026

Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Dr Harsh Shah, stomach cancer surgeon, Ahmedabad

Dr Harsh Shah
MS, MCh (Surgical Gastroenterology), DrNB (Surgical Gastroenterology)
Registered with Gujarat Medical Council, Reg. No. G-38738
Stomach Cancer Surgeon
Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad · 18 years of experience

In short

A GIST is a tumour driven by one faulty switch inside its cells. Most often the switch is a gene called KIT. Less often it is PDGFRA, or the SDH group of genes.

Which gene is at fault, and where, decides the tablet, the dose and how long you need it. One result, PDGFRA D842V, means the usual tablet imatinib will not work.

So the gene report is not a formality. Ask for it in every GIST that is large, high risk or has spread.

For the whole story of GIST, from the first test to imatinib and surgery, read our GIST treatment in Ahmedabad page. This post explains what your pathology and gene report actually says.

What cell does a GIST start from?

A GIST starts from the interstitial cells of Cajal. These are the gut’s pacemaker cells, which set the rhythm of the muscle wall that moves food along.

  • These cells carry a switch protein called KIT on their surface. A GIST cell has this switch stuck in the on position.
  • That is why a GIST grows from the muscle layer of the gut wall and pushes inward as a smooth bulge.
  • The cells are most dense in the stomach and small bowel, which is where most GISTs are found.

Where these tumours sit, and how common they are, is covered in our post on how common GIST is and what types exist.

What does the pathologist see under the microscope?

The pathologist describes the shape of the cells, counts how many are dividing, and notes whether the tumour was intact when removed. Each of these changes the plan.

  • Spindle-shaped cells are the usual picture. Round, epithelioid cells are seen less often and are linked to certain gene changes.
  • The count of dividing cells, given per a fixed area of the slide, shows how fast the tumour grows. It is one of the main parts of the risk group.
  • A GIST has a thin skin of squeezed normal tissue around it, not a true capsule. If that skin is torn, tumour cells can spill into the belly.
  • A tumour that burst before or during surgery is higher risk whatever its size, so surgeons handle it without squeezing or grasping it.

Size, the dividing-cell count and the site together give the risk group. Our post on how surgery and imatinib are put in order shows how that group guides the tablets.

Which stains confirm that it is a GIST?

Two stains matter most, KIT (also called CD117) and DOG1. Used together with the clinical picture, they settle the diagnosis in nearly every case.

  • KIT is the first stain asked for. It is positive in nearly all GISTs, but other tumours can also stain, so it cannot stand alone.
  • DOG1 confirms the diagnosis and rescues the few GISTs that are KIT-negative. Ask whether both were done.
  • CD34 is positive in many GISTs and adds support, though it is less reliable.
  • Other stains, such as desmin, S100 and beta-catenin, are used to rule out lookalikes such as muscle tumours, nerve tumours and desmoid.

A tumour that looks like a GIST on the scan can turn out to be something else. This is why the stains are read together, and why a biopsy is not skipped. Our post on how a GIST is confirmed with CT, scope and biopsy covers how the sample is taken.

What do the gene results mean for treatment?

The gene result tells us which medicine the tumour will respond to. This is the part of the report that changes treatment the most.

Common GIST gene results and what each one means for you
Gene resultHow the tumour tends to behaveWhat it means for treatment
KIT exon 11 (the commonest KIT change)Responds well to imatinib; a deletion at one spot, codons 557 and 558, tends to return soonerUsual imatinib dose; tablets after surgery are strongly considered when a deletion is found
KIT exon 9Seen more in the small bowel; imatinib works but needs moreA higher imatinib dose when the disease has spread
KIT exon 13 or 17Uncommon; the tablet may work only in part or stop working earlyLater medicines such as sunitinib may be needed sooner
PDGFRA, not D842VUsually in the stomach, often slow growingImatinib works; used if the risk group calls for it
PDGFRA D842VUsually in the stomach, often slow growingImatinib does not work; avapritinib is used if medicine is needed
SDH-deficient (no KIT or PDGFRA change)Younger patients, stomach, often several lumps; may reach lymph glandsImatinib helps little; surgery and careful watching come first

The table is a guide to the pattern, not a promise for any one person. Your own result is read together with the size, site and risk group of your tumour.

Why is PDGFRA D842V a special case?

Because the usual tablet cannot grip this change. Giving imatinib for it only loses time, so the gene report must be in hand before the tablet is chosen.

  • PDGFRA is a close cousin of KIT and also sits in the stomach wall, so its tumours look much like any other GIST.
  • These tumours are often epithelioid and may even stain weakly for KIT, which is one reason DOG1 is also asked for.
  • Avapritinib is made for this change. It is used when the disease has spread or cannot be removed.
  • If the tumour can be removed whole, surgery is done and the tumour is watched. There is no tablet that clearly helps afterwards.

Our post on the key GIST studies and what is new sets out the research behind avapritinib.

What is an SDH-deficient GIST?

It is a different disease that looks like a GIST. The tumour has lost a part of the cell’s energy machinery, called SDH, and it behaves in its own way.

  • It is seen mostly in children, teenagers and young adults, and is more often found in girls and women.
  • It sits in the stomach, often as several small lumps rather than one.
  • It is the one type of GIST that can reach nearby lymph glands, so the surgeon may sample them.
  • It often grows slowly, and many patients live for years even if it has spread.
  • A stain called SDHB shows whether SDH has been lost. It is asked for when a patient is young or no KIT or PDGFRA change is found.

A lost SDHB stain can point to a family condition. A rare pattern, Carney triad, joins a stomach GIST to a lung growth and a tumour near the nerves. When SDH is lost, a genetics doctor checks whether the change was inherited, and relatives may be offered checks.

What if no KIT, PDGFRA or SDH change is found?

A small group of GISTs have none of these. A wider gene panel is then sent, because a few of these rare changes have a medicine made for them.

  • NF1 is a gene linked to a nerve skin condition, and the GISTs it causes are mostly in the small bowel and often several.
  • NTRK fusions are very rare, but tablets such as larotrectinib work well against them.
  • A BRAF change can be treated with a targeted drug pair, though this is used case by case.
  • If nothing is found, a clinical trial is usually the better route than guessing with a standard tablet.

This is why a first report that says only “KIT-positive” is not the end. It tells you the stain was positive. It does not tell you the gene change.

What tissue is sent for a gene test, and when?

The wax-embedded block from the biopsy or from the operation is sent to a reference laboratory. The minimum test reads the main parts of KIT and PDGFRA.

  • Ask the laboratory to keep the block. A slide alone is often not enough for gene work.
  • The test is a must when the disease has spread, and when the tumour is large or high risk and tablets are being considered.
  • It is optional for a very small, low-risk tumour that was removed whole, though it can still guide how long to watch.
  • When imatinib stops working, a fresh biopsy or a blood test can show what new change has appeared.

Laboratories in India, including large cancer centres, run these panels. The result usually takes a couple of weeks, and the wider panel a little longer, so the sample is sent early and not left until the day tablets are due.

What should you ask about your own report?

Four questions cover it. Ask them at your next visit, with the report in hand.

  1. Which gene was tested, and which exon was changed?
  2. Was DOG1 done, along with KIT?
  3. What is the risk group, and was the tumour intact when it came out?
  4. Does the result change the tablet, its dose or how long I take it?

If any answer is missing, the report is not yet complete. Dr Shah will go through it with you and order what is missing.

Frequently asked questions

What is a gene test in GIST, and why is it done?

It reads the tumour's DNA to find which switch is stuck on, most often KIT or PDGFRA. The answer tells the team which tablet will work and at what dose.

Does every GIST need a gene test?

Not every one. It is a must when the disease has spread, and when a tumour is large or high risk and tablets are planned. A very small, low-risk tumour may not need it.

My report says KIT-positive. Is that the gene result?

No. KIT-positive is a stain on the slide. It confirms the type of tumour. The gene result is a separate test that names the exact change.

Why can PDGFRA D842V not be treated with imatinib?

This change keeps the target in a shape the tablet cannot bind. Imatinib would not slow the tumour, so a different medicine, avapritinib, is used if medicine is needed.

What does SDH-deficient mean?

The tumour has lost part of the cell's energy machinery. It is seen in younger people, sits in the stomach, may spread to lymph glands and responds poorly to imatinib.

Can a GIST run in the family?

Rarely. Most are not inherited. A GIST with lost SDH, or with NF1, can be part of a family condition, so a genetics doctor may check and relatives may be offered tests.

What if my tumour has no KIT or PDGFRA change?

A wider gene panel is sent. It looks for SDH loss, NF1, NTRK and BRAF changes. Some of these have a medicine made for them, and a trial may also be an option.

Related pages

For the full picture of GIST and its treatment, start at the GIST treatment in Ahmedabad page. For questions before you travel, call +91-63555-64601.

Where Dr Harsh Shah sees patients and operates

Dr Harsh Shah — Dr. Jivraj Mehta Hospital, Vasna, Ahmedabad
Dr. Jivraj Mehta Hospital, Dr Jivraj Mehta Marg, Vasna, Ahmedabad 380007.
Consultations, review of reports and scans, operations and follow-up. OPD Monday to Saturday, 9 am to 5 pm.
Appointments: +91-63555-64601 · +91-63590-11009 · Hospital 079-2663 6363
Directions to the hospital · WhatsApp +91-63555-64601

Handed a GIST report full of terms like KIT, exon 11, PDGFRA or SDH, and not sure what they mean for you? These words are not just labels. They tell the team which medicine will work, which will not, and how closely you need to be watched. Dr Harsh Shah, a stomach cancer surgeon in Ahmedabad, reads your pathology and gene report with you in plain words. Bring the report along. You can call us or book by message. Call For Appointment Book on WhatsApp Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Tapping Book on WhatsApp will likely open the WhatsApp app on your phone.

Get health updates from Dr Harsh Shah on WhatsApp

Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.

Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.

Dr. Harsh J Shah
Dr Harsh Shah, Gastro, Cancer & Laparoscopic Surgeon, Ahmedabad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.